Clinical Trial

A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is ongoing to explore the efficacy and safety of different strengths of SHR-3045 injection in moderate to severe active rheumatoid arthritis.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-02
notable Primary completion moved earlier: 2026-07 -> 2026-04-21 2026-05-02
Trial Details
NCT Number NCT07233655
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Moderate to Severe Active Rheumatoid Arthritis
Enrollment 30 participants
Start Date 2026-01-19
Primary Completion 2026-04-21 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-01